Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:8 Number:173 ISSN#:2563-5476
ACE Report #767
Ace Report Cover Arthroplasty

Aprotinin reduces blood transfusion in patients undergoing total hip arthroplasty

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Randomized Study of Aprotinin Effect on Transfusions and Blood Loss in Primary THA

Clin Orthop Relat Res. 2007 Dec;465:189-95

Contributing Authors: Colwell CW JE Chelly JM Murkin D Stevens TJ O'Keefe R Hall J Parvizi

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


393 patients undergoing elective primary total hip arthroplasty (THA) were randomized to receive aprotinin (a blood-conserving drug) or a placebo. The primary outcomes were the requirement for transfusions and blood loss. Results from this study indicated the use of aprotinin significantly reduces the requirement for blood transfusions when compared to a placebo treatment. No significant differenc...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.